Miscasting Patent Linkage
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In what can only be described as a slow news period for pharma IP policy, the arcane yet important issue of patent linkage has resurfaced in not once but […]
